Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Vitekta
Synonyms :
elvitegravir
Class :
Antiviral agents and Anti-HIV (antiretroviral)
Dosage Forms & Strengths
Tablet, Oral:
85 mg
150 mg
elvitegravir: they may diminish the serum concentration of antacids
elvitegravir: they may diminish the serum concentration of antacids
elvitegravir: they may diminish the serum concentration of antacids
elvitegravir: they may diminish the serum concentration of antacids
elvitegravir: they may diminish the serum concentration of antacids
Sucralfate may diminish the serum concentration of elvitegravir
may diminish the serum concentration of polyvalent cation containing products
may diminish the serum concentration of polyvalent cation-containing products
nafcillin will decrease the effect of action of elvitegravir by affecting enzyme CYP3A4 metabolism.
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elvitegravir
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
elvitegravir: they may diminish the serum concentration of CYP3A4 Inducers
elvitegravir: they may diminish the serum concentration of CYP3A4 Inducers
elvitegravir: they may diminish the serum concentration of CYP3A4 Inducers
elvitegravir: they may diminish the serum concentration of CYP3A4 Inducers
elvitegravir: they may diminish the serum concentration of CYP3A4 Inducers
it may diminish the metabolism when combined with azelastine
It may enhance the risk of adverse effects when combined with Anticonvulsants
It may enhance the risk of adverse effects when combined with Anticonvulsants
It may enhance the risk of adverse effects when combined with Anticonvulsants
It may enhance the risk of adverse effects when combined with Anticonvulsants
When elvitegravir is used together with adenine, this leads to a reduction in the elvitegravir's metabolism
the effect of elvitegravir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
idelalisib increases the effect or level of elvitegravir by altering the intestinal/hepatic CYP3A4 metabolism
the rate of metabolism of tocofersolan may be reduced with elvitegravir
Frequency defined:
>10%
Skin rash
Increased serum cholesterol
1% to 10%:
Angina pectoris
Facial edema
Myocardial infarction
Syncope
Peripheral neuropathy
Abnormal dreams
Anxiety
Confusion
Drowsiness
Disorientation
Disturbance in attention
Nervousness
Hypoesthesia
Prurigo
Night sweats
Xeroderma
Diabetes
lipohypertrophy
pancreatitis
stomatitis
anorexia
flatulence
gastritis
Post-marketing:
Angioedema
Erythema multiforme
Hemorrhagic stroke
Rhabdomyolysis
Stevens-Johnson syndrome
Dress syndrome
Pregnancy consideration: Elvitegravir may be used for antiretroviral therapy in pregnant patients. Consider dose reduction to avoid hematologic toxicity.
Lactation: Elvitegravir can be present in breast milk.Â
Pregnancy category:
Patient information leaflet
Generic Name: Elvitegravir
Pronunciation: Elvitegravir
Why do we use Elvitegravir?
It is used to treat viral infections such as HIV infection.